{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:24:10Z","timestamp":1780363450585,"version":"3.54.1"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK Government\u2019s Foreign, Commonwealth & Development Office"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220211"],"award-info":[{"award-number":["220211"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A qualitative study was conducted in Nigeria and Burkina Faso and comprised in-depth interviews (n = 68) and focus group discussions (n = 11) with key actor groups in the innovation system of antimalarial therapies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Evidence of ACT failure in African countries and explicit support for TACTs by the World Health Organization (WHO) and international funders were perceived important determinants for the market prospects of TACTs in Nigeria and Burkina Faso. At the country level, slow regulatory and implementation procedures were identified as potential barriers towards rapid TACTs deployment. Integrating TACTs in public sector distribution channels was considered relatively straightforward. More challenges were expected for integrating TACTs in private sector distribution channels, which are characterized by patient demand and profit motives. Finally, several affordability and acceptability issues were raised for which ACTs were suggested as a benchmark.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The market prospects of TACTs in Nigeria and Burkina Faso will depend on the demonstration of the added value of TACTs over ACTs, their advocacy by the WHO, the inclusion of TACTs in financial and regulatory arrangements, and their alignment with current distribution and deployment practices. Further clinical, health-economic and feasibility studies are required to inform decision makers about the broader implications of a transition to TACTs in African counties. The recent reporting of artemisinin resistance and ACT failure in Africa might change important determinants of the market readiness for TACTs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0256567","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T18:07:20Z","timestamp":1630433240000},"page":"e0256567","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-0983","authenticated-orcid":true,"given":"Freek","family":"de Haan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladimeji Akeem","family":"Bolarinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemonde","family":"Guissou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Tou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Tindana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter P. C.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen H. M.","family":"Moors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaik Yeong","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Dhorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen M.","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0412-8733","authenticated-orcid":true,"given":"Jean Bosco","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olugbenga A.","family":"Mokuolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanaki","family":"Amaratunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"pone.0256567.ref001","unstructured":"WHO. WHO briefing on Malaria Treatment Guidelines and artemisinin monotherapies. Geneva; 2006. http:\/\/apps.who.int\/malaria\/docs\/Meeting_briefing19April.pdf"},{"key":"pone.0256567.ref002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1473-3099(15)00487-9","article-title":"Dihydroartemisinin-piperaquine resistance in plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study","volume":"16","author":"C Amaratunga","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pone.0256567.ref003","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/ciw388","article-title":"Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003\u20132013): The Role of Parasite Genetic Factors","volume":"63","author":"AP Phyo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pone.0256567.ref004","first-page":"3099","article-title":"Articles Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study","author":"RW van der Pluijm","year":"2019","journal-title":"Lancet"},{"key":"pone.0256567.ref005","first-page":"1","article-title":"Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia","author":"M Mairet-Khedim","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0256567.ref006","unstructured":"WHO. World malaria report 2019. WHO Reg Off Africa. Geneva; 2019."},{"key":"pone.0256567.ref007","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response 10 years of surveillance (2010\u20132019). Geneva; 2020."},{"key":"pone.0256567.ref008","first-page":"13","article-title":"Artemisinin resistance-modelling the potential human and economic costs","author":"Y Lubell","year":"2014","journal-title":"Malar J"},{"key":"pone.0256567.ref009","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nrd4573","article-title":"Malaria medicines: A glass half full?","volume":"14","author":"TNC Wells","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"pone.0256567.ref010","first-page":"1","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"JN Burrows","year":"2017","journal-title":"Malar J"},{"key":"pone.0256567.ref011","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40265-018-0911-9","article-title":"Drugs in Development for Malaria","volume":"78","author":"EA Ashley","year":"2018","journal-title":"Drugs"},{"key":"pone.0256567.ref012","first-page":"1","article-title":"The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies","volume":"13","author":"MF Boni","year":"2016","journal-title":"PLoS Med"},{"key":"pone.0256567.ref013","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pt.2017.01.004","article-title":"Seidlein L von. How to Contain Artemisinin- and Multidrug-Resistant Falciparum Malaria","volume":"33","author":"AM Dondorp","year":"2017","journal-title":"Trends Parasitol"},{"key":"pone.0256567.ref014","first-page":"1","article-title":"Challenges to replace ACT as first-line drug","volume":"16","author":"AP Phyo","year":"2017","journal-title":"Malar J"},{"key":"pone.0256567.ref015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","article-title":"Triple Artemisinin-Based Combination Therapies for Malaria\u2013A New Paradigm?","volume":"37","author":"RW van der Pluijm","year":"2021","journal-title":"Trends Parasitol"},{"key":"pone.0256567.ref016","first-page":"18","article-title":"Triple ACT should be implemented now to delay the emergence of resistance","author":"N White","year":"2019","journal-title":"Malar J"},{"key":"pone.0256567.ref017","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"RW van der Pluijm","year":"2020","journal-title":"Lancet"},{"key":"pone.0256567.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-6-1","article-title":"The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya","volume":"6","author":"AA Amin","year":"2007","journal-title":"Malar J"},{"key":"pone.0256567.ref019","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4269\/ajtmh.2007.77.193","article-title":"A major transition in malaria treatment: The adoption and deployment of artemisinin-based combination therapies","volume":"77","author":"A Bosman","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0256567.ref020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-3156.2006.01590.x","article-title":"The costs of changing national policy: Lessons from malaria treatment policy guidelines in Tanzania","volume":"11","author":"JA Mulligan","year":"2006","journal-title":"Trop Med Int Heal"},{"key":"pone.0256567.ref021","first-page":"183","article-title":"Countering Drug Resistance in the Developing World: An Assessment of Incentives across the Value Chain and Recommendations for Policy Interventions","author":"P Yadav","year":"2009","journal-title":"CGD Work Pap"},{"key":"pone.0256567.ref022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.eist.2021.05.003","article-title":"Market Formation in a Global Health Transition","volume":"40","author":"F de Haan","year":"2021","journal-title":"Environ Innov Soc Transitions"},{"key":"pone.0256567.ref023","first-page":"1","article-title":"Deploying triple artemisinin \u2011 based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations","author":"P Tindana","year":"2021","journal-title":"Malar J"},{"key":"pone.0256567.ref024","volume-title":"Case Study Research, Design and Methods","author":"RK Yin","year":"2003","edition":"5"},{"key":"pone.0256567.ref025","doi-asserted-by":"crossref","unstructured":"Edquist C. Systems of innovation: Technologies, institutions and organizations. de la Mothe J, editor. Long Range Planning. Abington: Routledge Taylor & Francin Group; 1997. doi: 10.1016\/s0024-6301(98)90244-8","DOI":"10.1016\/S0024-6301(98)90244-8"},{"key":"pone.0256567.ref026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.techfore.2017.11.011","article-title":"Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands","volume":"128","author":"EHM Moors","year":"2018","journal-title":"Technol Forecast Soc Change"},{"key":"pone.0256567.ref027","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/160940690600500107","article-title":"Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development","volume":"5","author":"J Fereday","year":"2006","journal-title":"Int J Qual Methods"},{"key":"pone.0256567.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/wellcomeopenres.16065.1","article-title":"Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol","volume":"6","author":"P Tindana","year":"2021","journal-title":"Wellcome Open Res"},{"key":"pone.0256567.ref029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(03)15330-5","article-title":"WHO, the global fund and medical malpractice in malaria treatment","volume":"363","author":"A Attaran","year":"2004","journal-title":"Lancet"},{"key":"pone.0256567.ref030","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"A Uwimana","year":"2020","journal-title":"Nat Med"},{"key":"pone.0256567.ref031","first-page":"1","article-title":"Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania","volume":"10","author":"GM Bwire","year":"2020","journal-title":"Nat Res"},{"key":"pone.0256567.ref032","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study","author":"A Uwimana","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pone.0256567.ref033","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1473-3099(20)30493-X","article-title":"Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review","volume":"21","author":"NK Kayiba","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pone.0256567.ref034","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","article-title":"Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance across Uganda","volume":"223","author":"V Asua","year":"2021","journal-title":"J Infect Dis"},{"key":"pone.0256567.ref035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3201\/eid2701.203527","article-title":"Increase in Kelch 13 Polymorphisms in Plasmodium","volume":"27","author":"C Bergmann","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"pone.0256567.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01949-20","article-title":"Continued low efficacy of artemether-lumefantrine in Angola in 2019","volume":"65","author":"PR Dimbu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0256567.ref037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-021-03585-6","article-title":"Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018","volume":"20","author":"A Gansan\u00e9","year":"2021","journal-title":"Malar J"},{"key":"pone.0256567.ref038","first-page":"1","article-title":"Is there evidence of anti \u2011 malarial multidrug resistance in Burkina Faso?","author":"C Rasmussen","year":"2021","journal-title":"Malar J"},{"key":"pone.0256567.ref039","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/heapol\/czh051","article-title":"The process of changing national malaria treatment policy: Lessons from country-level studies","volume":"19","author":"HA Williams","year":"2004","journal-title":"Health Policy Plan"},{"key":"pone.0256567.ref040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12936-017-1818-8","article-title":"Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries","volume":"16","author":"PN Newton","year":"2017","journal-title":"Malar J"},{"key":"pone.0256567.ref041","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/heapol\/czv031","article-title":"Prices and mark-ups on antimalarials: Evidence from nationally representative studies in six malaria-endemic countries","volume":"31","author":"B Palafox","year":"2016","journal-title":"Health Policy Plan"},{"key":"pone.0256567.ref042","first-page":"16","article-title":"What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism","author":"S Tougher","year":"2017","journal-title":"Malar J"},{"key":"pone.0256567.ref043","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/1475-2875-10-326","article-title":"Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries","volume":"10","author":"KA O\u2019Connell","year":"2011","journal-title":"Malar J"},{"key":"pone.0256567.ref044","first-page":"9","article-title":"Understanding private sector antimalarial distribution chains: A cross-sectional mixed methods study in six malaria-endemic countries","author":"B Palafox","year":"2014","journal-title":"PLoS One"},{"key":"pone.0256567.ref045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-10-325","article-title":"The ACTwatch project: Methods to describe anti-malarial markets in seven countries","volume":"10","author":"T Shewchuk","year":"2011","journal-title":"Malar J"},{"key":"pone.0256567.ref046","first-page":"18","article-title":"Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance: the case against","author":"S Krishna","year":"2019","journal-title":"Malar J"},{"key":"pone.0256567.ref047","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/S0140-6736(20)32400-4","article-title":"Triple artemisinin-based combination therapies for malaria: proceed with caution","volume":"396","author":"J Wang","year":"2020","journal-title":"Lancet"},{"key":"pone.0256567.ref048","volume-title":"Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance","author":"KJ Arrow","year":"2004"},{"key":"pone.0256567.ref049","first-page":"15","article-title":"Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys","author":"J Novotny","year":"2016","journal-title":"Malar J"},{"key":"pone.0256567.ref050","first-page":"10","article-title":"Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: Baseline results and implications for programming in six African countries","author":"M Littrell","year":"2011","journal-title":"Malar J"},{"key":"pone.0256567.ref051","first-page":"22","article-title":"Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs","author":"T Sullivan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"pone.0256567.ref052","doi-asserted-by":"crossref","first-page":"403","DOI":"10.15171\/ijhpm.2016.30","article-title":"What Can we Learn About the Processes of Regulation of Tuberculosis Medicines From the Experiences of Health Policy and System Actors in India, Tanzania, and Zambia?","volume":"5","author":"K Sheikh","year":"2016","journal-title":"Int J Heal Policy Manag"},{"key":"pone.0256567.ref053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2019-029141","article-title":"Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: A qualitative study","volume":"9","author":"T Sunyoto","year":"2019","journal-title":"BMJ Open"},{"key":"pone.0256567.ref054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-9-164","article-title":"Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets\u2014A provider perspective","volume":"9","author":"S Alba","year":"2010","journal-title":"Malar J"},{"key":"pone.0256567.ref055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6963-8-119","article-title":"A qualitative study of the feasibility and community perception on the effectiveness of artemether-lumefantrine use in the context of home management of malaria in south-west Nigeria","volume":"8","author":"IO Ajayi","year":"2008","journal-title":"BMC Health Serv Res"},{"key":"pone.0256567.ref056","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4269\/ajtmh.2009.80.326","article-title":"Review: Provider practice and user behavior interventions to improve prompt and effective treatment of malaria: Do we know what works?","volume":"80","author":"LA Smith","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0256567.ref057","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.techfore.2006.03.002","article-title":"Smits REHM. Functions of innovation systems: A new approach for analysing technological change","volume":"74","author":"MP Hekkert","year":"2007","journal-title":"Technol Forecast Soc Change"},{"key":"pone.0256567.ref058","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/heapol\/czs088","article-title":"Health systems, systems thinking and innovation","volume":"27","author":"R Atun","year":"2012","journal-title":"Health Policy Plan"},{"key":"pone.0256567.ref059","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/heapol\/czs084","article-title":"Systems thinking for strengthening health systems in LMICs: Need for a paradigm shift","volume":"27","author":"T Adam","year":"2012","journal-title":"Health Policy Plan"},{"key":"pone.0256567.ref060","first-page":"1","article-title":"The application of systems thinking in health: Why use systems thinking?","volume":"12","author":"DH Peters","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"pone.0256567.ref061","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.eist.2019.11.006","article-title":"Market formation in the context of transitions: A comment on the transitions agenda","volume":"34","author":"WPC Boon","year":"2020","journal-title":"Environ Innov Soc Transitions"},{"key":"pone.0256567.ref062","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1146\/annurev-environ-102014-021340","article-title":"Sustainability Transitions Research: Transforming Science and Practice for Societal Change","volume":"42","author":"D Loorbach","year":"2017","journal-title":"Annu Rev Environ Resour"},{"key":"pone.0256567.ref063","article-title":"Technological Innovation System Analysis\u2014a manual for analysts","author":"M Hekkert","year":"2011","journal-title":"Technol Innov Syst Anal"},{"key":"pone.0256567.ref064","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.drudis.2014.03.004","article-title":"Towards a sustainable system of drug development","volume":"19","author":"EHM Moors","year":"2014","journal-title":"Drug Discov Today"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T18:08:27Z","timestamp":1630433307000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256567"}},"subtitle":[],"editor":[{"given":"Lucy C.","family":"Okell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":64,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0256567","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]}}}